IDEXX LABORATORIES, INC. (NASDAQ:IDXX) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07
| Submission of Matters to a Vote of Security Holders. |
On May 3, 2017, IDEXX Laboratories, Inc. (the Company) held its
2017 annual meeting of stockholders (the Annual Meeting), at
which a quorum was present in person or by proxy.
At the Annual Meeting, stockholders considered and voted on the
following proposals, each of which is described in more detail in
the Companys proxy statement dated March 23, 2017, (the Proxy
Statement): (1) the election of three Class II directors for
terms expiring at the 2020 annual meeting of stockholders; (2)
the ratification of the appointment of PricewaterhouseCoopers LLP
as the Company’s independent registered accounting firm for the
current fiscal year; (3) the approval, on an advisory basis, of
the compensation of the Company’s named executive officers; and
(4) an advisory vote on how frequently we should seek an advisory
vote on the compensation of our named executive officers as
presented in the Company’s proxy statement delivered to
stockholders in connection with the Annual Meeting.
The voting results at the Annual Meeting with respect to each of
the matters described above, were as follows:
| Proposal One: | Election of Directors |
|
Nominees |
For |
Against |
Abstain |
Broker Non-Votes |
||||
| Rebecca M. Henderson, PhD | 69,701,078 | 1,440,416 | 31,660 | 8,978,293 | ||||
| Lawrence D. Kingsley | 70,831,533 | 304,217 | 37,404 | 8,978,293 | ||||
| Sophie V. Vandebroek, PhD | 67,914,847 | 3,230,036 | 28,271 | 8,978,293 |
| Proposal Two: |
Ratification of Appointment of Independent Registered |
| For | 79,240,456 |
| Against | 879,502 |
| Abstain | 31,489 |
| Broker Non-Votes | N/A |
| Proposal Three: |
Advisory Vote to Approve Executive Compensation |
| For | 64,921,042 |
| Against | 6,160,819 |
| Abstain | 91,293 |
| Broker Non-Votes | 8,978,293 |
| Proposal Four: |
Advisory Vote on Frequency of Approval of Executive |
| One Year | 65,065,303 |
| Two Years | 84,157 |
| Three Years | 5,942,572 |
| Abstain | 81,122 |
| Broker Non-Votes | 8,978,293 |
| Item 8.01 | Other Events. |
On May 2, 2017, the Companys Board of Directors authorized an
increase in the Companys ongoing share repurchase program,
authorizing the repurchase of up to three million additional
shares of the Companys Common Stock for a total of sixty-eight
million shares as of May 2, 2017. Repurchases may be made in the
open market (including through Rule 10b5-1 plans) or in
negotiated transactions. These shares are in addition to the
3,297,887 shares remaining under the Companys ongoing share
repurchase program as of April 28, 2017, to previous Board
authorization. The timing and amount of any repurchases will be
at the discretion of the Company’s management. The increase in
the number of shares authorized under the share repurchase plan
is described in a press release issued by the Company on May 3,
2017, which is attached hereto as Exhibit 99.1.
| Item 9.01 | Financial Statements and Exhibits. |
| (d) | Exhibits |
The following exhibit is furnished as part of this Report to Item
8.01.
| 99.1 |
Press Release entitled IDEXX Laboratories Announces Increase in Share Repurchase Program issued by the Company on May 3, 2017. |
About IDEXX LABORATORIES, INC. (NASDAQ:IDXX)
IDEXX Laboratories, Inc. develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company’s segments include Companion Animal Group (CAG), which develops, designs, manufactures and distributes products and performs services for veterinarians and the bioresearch market; Water, which develops, designs, manufactures and distributes a range of products used in the detection of various microbiological parameters in water; Livestock, Poultry and Dairy (LPD), which develops, designs, manufactures and distributes diagnostic tests and related instrumentation, and performs services that are used to manage the health status of livestock and poultry and to expand bovine reproductive productivity, and Other, which develops, designs, manufactures and distributes point-of-care electrolyte and blood gas analyzers and related consumable products for the human medical diagnostics market. IDEXX LABORATORIES, INC. (NASDAQ:IDXX) Recent Trading Information
IDEXX LABORATORIES, INC. (NASDAQ:IDXX) closed its last trading session up +1.55 at 162.01 with 789,251 shares trading hands.
